Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer

Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Regorafenib is still in the early stages of development in gastric cancer, says Cusnir. Although regorafenib has shown activity in this space, it is also one of the more toxic agents. As such, it is unknown what its optimal role will be in the treatment paradigm.

In colorectal cancer, the phase II ReDOS trial demonstrated that a dose-escalation strategy could be used with regorafenib to reduce associated adverse events and maintain efficacy; however, it is unknown whether the same holds true in gastric cancer. In the absence of those data, the field is looking toward larger confirmatory trials to establish whether regorafenib has a role in subsequent lines of gastric cancer treatment, concludes Cusnir.